The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ditropan     4-diethylaminobut-2-ynyl 2-cyclohexyl-2...

Synonyms: Anturol, Cystrin, Oxytrol, Pollakisu, Oxybutinin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Oxytrol


Psychiatry related information on Oxytrol


High impact information on Oxytrol


Chemical compound and disease context of Oxytrol


Biological context of Oxytrol

  • It is as potent as oxybutynin in inhibiting bladder contraction, but is much less potent in inhibiting salivation, suggesting that it may have less propensity to cause dry mouth in clinical use [19].
  • These patients were compared to those not using oxybutynin with regard to urodynamic parameters and upper tract deterioration [20].
  • CONCLUSIONS: Accelerated intravesical administration results in greater bioavailability and increased objective benefits without side effects in previously unresponsive patients compared with oral and intravesical passive diffusion oxybutynin administration [21].
  • The ratio for the AUC values for N-desethyl-oxybutynin and oxybutynin was 2.1 +/- 0.2 (n = 11) [22].
  • CONCLUSIONS: Oxybutynin, a commonly used pharmacological agent in pediatric urology, was not associated with cognitive impairment following treatment [8].

Anatomical context of Oxytrol


Associations of Oxytrol with other chemical compounds


Gene context of Oxytrol


Analytical, diagnostic and therapeutic context of Oxytrol

  • Oxybutynin XL efficacy and side-effect data obtained from two parallel-group, randomized, controlled clinical trials were modeled to evaluate the therapeutic index [2].
  • Hence, given its overall efficacy/tolerability profile and dosage flexibility, oxybutynin ER provides an excellent treatment option in the first-line pharmacotherapy of OAB [13].
  • In two randomised, double-blind studies in patients with OAB, the improvement in all the symptoms with once-daily oxybutynin ER 5-30 mg/day was similar to that produced by oxybutynin IR 5-20 mg/day given one to four times daily [13].
  • Intravesical instillation (0.2 mg./kg./dose), on the other hand, resulted in reduced metabolite generation and peak plasma concentrations for N-desethyl-oxybutynin which were in the same range as those for oxybutynin, the ratio being 1.2 +/- 0.1 (n = 11) [22].
  • Oral administration of oxybutynin (76.1 micromol/kg) showed significant binding of cerebral cortical muscarinic receptors in mice, as indicated by about a 2-fold increase in K(d) values for specific [(3)H]N-methylscopolamine binding 0.5 and 2 hours later [16].


  1. Oxybutynin for diabetic complications. Chideckel, E.W. JAMA (1990) [Pubmed]
  2. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Gupta, S.K., Sathyan, G., Lindemulder, E.A., Ho, P.L., Sheiner, L.B., Aarons, L. Clin. Pharmacol. Ther. (1999) [Pubmed]
  3. Hyperhidrosis and hypothermia responsive to oxybutynin. LeWitt, P. Neurology (1988) [Pubmed]
  4. Inhibition of hyperreflexia by vaginally administered oxybutynin: a novel rabbit model. Chou, E.C., Whitbeck, C., Borow, A., Burden, O., Levin, R.M. J. Urol. (2004) [Pubmed]
  5. Oxybutynin lowers elevated renal pelvic pressures in a rat congenital unilateral hydronephrosis. Fichtner, J., Boineau, F.G., Lewy, J.E., Shortliffe, L.M. J. Urol. (1998) [Pubmed]
  6. Oxybutynin, desmopressin and enuresis. Nevéus, T. J. Urol. (2001) [Pubmed]
  7. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction. Buyse, G., Verpoorten, C., Vereecken, R., Casaer, P. J. Urol. (1998) [Pubmed]
  8. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. Sommer, B.R., O'Hara, R., Askari, N., Kraemer, H.C., Kennedy, W.A. J. Urol. (2005) [Pubmed]
  9. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. Diefenbach, K., Arold, G., Wollny, A., Schwantes, U., Haselmann, J., Roots, I. BJU international. (2005) [Pubmed]
  10. Psychotic disorder induced by oxybutynin: Presentation of two cases. Gulsun, M., Pinar, M., Sabanci, U. Clinical drug investigation (2006) [Pubmed]
  11. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Sathyan, G., Dmochowski, R.R., Appell, R.A., Guo, C., Gupta, S.K. Clinical pharmacokinetics. (2004) [Pubmed]
  12. Trospium chloride in the management of overactive bladder. Rovner, E.S. Drugs (2004) [Pubmed]
  13. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Siddiqui, M.A., Perry, C.M., Scott, L.J. Drugs (2004) [Pubmed]
  14. Clinical pharmacokinetics of drugs used to treat urge incontinence. Guay, D.R. Clinical pharmacokinetics. (2003) [Pubmed]
  15. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. Malone-Lee, J., Shaffu, B., Anand, C., Powell, C. J. Urol. (2001) [Pubmed]
  16. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. Oki, T., Kageyama, A., Takagi, Y., Uchida, S., Yamada, S. J. Urol. (2007) [Pubmed]
  17. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. Fader, M., Glickman, S., Haggar, V., Barton, R., Brooks, R., Malone-Lee, J. J. Urol. (2007) [Pubmed]
  18. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. Gajewski, J.B., Awad, S.A. J. Urol. (1986) [Pubmed]
  19. Tolterodine. Hills, C.J., Winter, S.A., Balfour, J.A. Drugs (1998) [Pubmed]
  20. The role of oxybutynin in spinal cord injured patients with indwelling catheters. Kim, Y.H., Bird, E.T., Priebe, M., Boone, T.B. J. Urol. (1997) [Pubmed]
  21. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. Di Stasi, S.M., Giannantoni, A., Vespasiani, G., Navarra, P., Capelli, G., Massoud, R., Stephen, R.L. J. Urol. (2001) [Pubmed]
  22. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. Buyse, G., Waldeck, K., Verpoorten, C., Björk, H., Casaer, P., Andersson, K.E. J. Urol. (1998) [Pubmed]
  23. Oxybutynin administration diminishes the high gastric muscular tone associated with bladder reconstruction. Sheldon, C.A., Reeves, D., Lewis, A.G. J. Urol. (1995) [Pubmed]
  24. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. Oki, T., Toma-Okura, A., Yamada, S. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  25. Oxybutynin decreases renal pelvic pressures in normal and infected rat urinary tract. Cowan, B.E., Shortliffe, L.M. J. Urol. (1998) [Pubmed]
  26. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. Oki, T., Kimura, R., Saito, M., Miyagawa, I., Yamada, S. J. Urol. (2004) [Pubmed]
  27. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Palmer, L.S., Zebold, K., Firlit, C.F., Kaplan, W.E. J. Urol. (1997) [Pubmed]
  28. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. Maruyama, S., Oki, T., Otsuka, A., Shinbo, H., Ozono, S., Kageyama, S., Mikami, Y., Araki, I., Takeda, M., Masuyama, K., Yamada, S. J. Urol. (2006) [Pubmed]
  29. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. Nelson, C.P., Gupta, P., Napier, C.M., Nahorski, S.R., Challiss, R.A. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  30. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes. Lukkari, E., Taavitsainen, P., Juhakoski, A., Pelkonen, O. Pharmacol. Toxicol. (1998) [Pubmed]
  31. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. Noronha-Blob, L., Kachur, J.F. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  32. Intravesical electromotive drug administration technique: preliminary results and side effects. Riedl, C.R., Knoll, M., Plas, E., Pflüger, H. J. Urol. (1998) [Pubmed]
  33. Effects of oxybutynin on vesicoureteral reflux in children. Homsy, Y.L., Nsouli, I., Hamburger, B., Laberge, I., Schick, E. J. Urol. (1985) [Pubmed]
  34. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Oki, T., Sato, S., Miyata, K., Yamada, S. Br. J. Pharmacol. (2005) [Pubmed]
WikiGenes - Universities